Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 7/20 | 0.45 |
| ▸ | CA1 | P00915 | 7/20 | 0.45 |
| ▸ | CA2 | P00918 | 7/20 | 0.45 |
| ▸ | CA9 | Q16790 | 7/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21069640 | 0.97 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL13699512 | 0.97 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL25695638 | 0.97 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL3617073 | 0.97 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL21071644 | 0.97 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL23728812 | 0.97 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL1261192 | 0.97 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL29230312 | 0.94 | MEN1 (0.50) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL25194819 | 0.92 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL14958594 | 0.92 | TDP1 (0.51) | MEN1GAAKMT2ATDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113512035-B | Dihydropyrimidine-pomalidomide conjugate, and preparation method and application thereof | 山东大学 | 2023-11-24 | — | — | CN | claimed |
| CN-113512035-A | Dihydropyrimidine-pomalidomide conjugate and preparation method and application thereof | 山东大学 | 2021-10-19 | — | — | CN | claimed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| CN-121574171-A | Difunctional protein degradation agent of direct targeting proteasome, preparation method and application thereof | 浙大城市学院 | 2026-02-27 | — | — | CN | disclosed |
| EP-4695237-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4043447-B1 | HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVE, PREPARATION AND APPLICATION THEREOF | SHANGHAI QINGDONG BIOTECHNOLOGY CO LTD (CN) | 2026-01-21 | — | — | EP | disclosed |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| EP-4053126-B1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | BROADENBIO CO LTD (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | TERNS PHARMACEUTICALS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012004005-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004005-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004006-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004006-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| US-8084643-B2 | Nitrogen-containing esters of the secondary alcohol group of florfenicol and of its analogs,including salts; veterinary medicine; nonhydrolyzing as needed to maintain the prodrug in aqueous solution in the subjects system until appropriate; cattle drinking water; bovine respiratory disease | INTERVET INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110300174-A1 | CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION | PFIZER VACCINES LLC (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011151807-A1 | CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION | PFIZER VACCINES LLC (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20080188556-A1 | Water-Soluble Prodrugs of Florfenicol and its Analogs | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885GAA 1234/4885KMT2A 445/4885 |
| US-20110300174-A1 | CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION | CHRNG, CHRND, CHRNA3 | MEN1 1750/4885GAA 1418/4885KMT2A 741/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | MEN1 1933/4885GAA 3941/4885KMT2A 3953/4885 |
| US-20080188556-A1 | Water-Soluble Prodrugs of Florfenicol and its Analogs | PFAS, ADH5, SI | MEN1 2179/4885GAA 1057/4885KMT2A 1864/4885 |
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | ABL1, ABL2, BCR | MEN1 4339/4885GAA 961/4885KMT2A 122/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | MEN1 3715/4885GAA 640/4885KMT2A 2204/4885 |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | BRD9, BCL9L, BCL9 | MEN1 270/4885GAA 1384/4885KMT2A 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.